Compare LPA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | PMN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Costa Rica | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 84.1M |
| IPO Year | 2023 | 2022 |
| Metric | LPA | PMN |
|---|---|---|
| Price | $2.42 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | $7.00 | ★ $42.27 |
| AVG Volume (30 Days) | 23.0K | ★ 362.7K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.11 | N/A |
| Revenue Next Year | $10.81 | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $0.29 |
| 52 Week High | $4.38 | $27.40 |
| Indicator | LPA | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 30.68 |
| Support Level | $2.33 | $2.78 |
| Resistance Level | $2.72 | $15.05 |
| Average True Range (ATR) | 0.11 | 1.20 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 15.22 | 7.35 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.